KR950013508A - 수면 장애의 치료에 유용한 멜라토닌 유도체 - Google Patents

수면 장애의 치료에 유용한 멜라토닌 유도체 Download PDF

Info

Publication number
KR950013508A
KR950013508A KR1019940029487A KR19940029487A KR950013508A KR 950013508 A KR950013508 A KR 950013508A KR 1019940029487 A KR1019940029487 A KR 1019940029487A KR 19940029487 A KR19940029487 A KR 19940029487A KR 950013508 A KR950013508 A KR 950013508A
Authority
KR
South Korea
Prior art keywords
ethyl
acetamide
methoxy
methyl
hydrogen
Prior art date
Application number
KR1019940029487A
Other languages
English (en)
Inventor
에드워드 플라우 마이클
Original Assignee
피터 지. 스트링거
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피터 지. 스트링거, 일라이 릴리 앤드 캄파니 filed Critical 피터 지. 스트링거
Publication of KR950013508A publication Critical patent/KR950013508A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

본 발명은 다양한 메탈로닌 유사체를 사용하여 수면 장애를 치료하는 방법에 관한 것이다. 또한 본 발명은 이러한 방법에 사용하기 적합한 약학적 제제에 관한 것이다.

Description

수면 장애의 치료에 유용한 멜라토닌 유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (3)

  1. 수면 장애를 치료하는 약제를 제조하기 위한 하기 일반식의 화합물의 용도 :
    상기 식에서, R1은 수소, C1-C4알킬 또는 C1-C4알콕시이고; R2는 수소 또는 C1-C4알킬이고: R3은 수소, C1-C4알킬, 페닐 또는 치환된 페닐이고; R4는 수소, 할로아세틸, C1-C5알카노일, 벤조일, 또는 할로 또는 메틸에 의해 치환된 벤조일이며: R5와 R6은 각각 독립적이고 수소 또는 할로이고; R7은 수소 또는 C1-C4알킬이며', 단, R3, R4및 R5가 각각 수소인 경우 R2는 C1-C4알킬이어야 한다.
  2. 제1항에 있어서, N-[2-메틸-2-(5-메톡시-6-플루오로인돌-3-일)에틸]아세트아미드; N-[2-에틸-2-(5-메톡시-6-클로로인돌-3-일)에틸]아세트아미드; N-[2-메틸-2-(5-메톡시-6,7-디클로로인돌-3-일)에틸]아세트아미드; 또는 N-[2-메틸-2-(5-메 톡시-6-클로로인돌-3-일)에틸]아세트아미드로부터 선택되는 화합물을 사용하는 용도.
  3. 제1항에 있어서, N-[2-메틸-2(5-메톡시-6-클로로인돌-3-일)에틸]아세트아미드; (+)-N-[2-메틸-2-(5-메톡시-6-크로로인돌-3-일)에틸]아세트아미드; 또는 (-)-N-[2-메틸-2-(5-메톡시-6-클로로인돌-3-일)에틸]아세트아미드를 사용하는 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940029487A 1993-11-18 1994-11-11 수면 장애의 치료에 유용한 멜라토닌 유도체 KR950013508A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/154.332 1993-11-18
US08/154,332 US5654325A (en) 1993-11-18 1993-11-18 Melatonin derivatives for use in treating sleep disorders

Publications (1)

Publication Number Publication Date
KR950013508A true KR950013508A (ko) 1995-06-15

Family

ID=22550932

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940029487A KR950013508A (ko) 1993-11-18 1994-11-11 수면 장애의 치료에 유용한 멜라토닌 유도체

Country Status (21)

Country Link
US (1) US5654325A (ko)
EP (1) EP0655243B1 (ko)
JP (1) JPH07196493A (ko)
KR (1) KR950013508A (ko)
CN (1) CN1092958C (ko)
AT (1) ATE222491T1 (ko)
AU (1) AU684313B2 (ko)
CA (1) CA2135709C (ko)
CZ (1) CZ288835B6 (ko)
DE (1) DE69431199T2 (ko)
DK (1) DK0655243T3 (ko)
ES (1) ES2181702T3 (ko)
HU (1) HUT72069A (ko)
IL (1) IL111580A (ko)
NO (1) NO309964B1 (ko)
NZ (1) NZ264892A (ko)
PH (1) PH31098A (ko)
PT (1) PT655243E (ko)
RU (1) RU2146140C1 (ko)
SG (1) SG50505A1 (ko)
ZA (1) ZA948927B (ko)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0748627A3 (en) * 1995-06-14 1997-05-21 Lilly Co Eli Melatonin agonists for the treatment of benign forms of hyperplasia of the prostate
CA2357114C (en) * 2001-03-22 2010-06-29 Pooger Properties Ltd. Use of melatonin in the manufacture of a medicament for treating attention deficit hyperactive disorder
US20030096379A1 (en) * 2001-03-28 2003-05-22 Kilgore James L. Method for producing tryptamine derivatives
IL144900A (en) * 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
DE60313785T2 (de) * 2002-09-26 2008-01-24 Pooger Properties Ltd., St. Helier, Jersey Kombinierte verwendung von melatonin und methylphenidat zur behandlung von aufmerksamkeits-/hyperaktivitätsstörungen.
JP4933097B2 (ja) 2003-12-19 2012-05-16 株式会社メニコン 糖尿病および糖尿病合併症の治療・改善方法
US20070105937A1 (en) * 2003-12-22 2007-05-10 Miguel Pappolla Indole-3-propionamide and derivatives thereof
US7799817B2 (en) * 2004-02-20 2010-09-21 Lifescape Biosciences Inc Compositions and methods for sleep regulation
DE102005008312A1 (de) * 2005-02-17 2006-08-24 Birds Pharma Gmbh Berolina Innovative Research & Development Services Verwendung deuterierter N-[2-(5-Methoxy-1H-indol-3-yl)-ethyl]acatamide und deren pharmazeutisch verträglicher Salze sowie diese Verbindungen enthaltende Arzneimittel
US20060223877A1 (en) * 2005-03-31 2006-10-05 Zemlan Frank P Methods of treatment utilizing certain melatonin derivatives
AR061478A1 (es) * 2006-06-19 2008-08-27 Takeda Pharmaceutical Compuesto triciclico y composicion farmaceutica
ES2324849A1 (es) * 2007-10-25 2009-08-17 Ferrer Internacional, S.A. Compuestos de indano.

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4087444A (en) * 1976-09-08 1978-05-02 Eli Lilly And Company Amides as ovulation inhibitors
IT1148618B (it) * 1982-10-11 1986-12-03 Polifarma Spa Procedimento enzimatico per la produzione di acido 3-indolpiruvico e utilizzazione farmaceutica di questo
EP0126630B1 (en) * 1983-05-18 1987-09-16 Monash University The use of melatonin for the manufacture of a medicament
US4600723A (en) * 1983-05-18 1986-07-15 Monash University Method for minimizing disturbances in circadian rhythms of bodily performance and function
US4614807A (en) * 1984-10-04 1986-09-30 Eli Lilly And Company 6,7-dihalomelatonins
US4687763A (en) * 1985-02-25 1987-08-18 Massachusetts Institute Of Technology Composition and method for increasing levels or release of brain serotonin
US4997845A (en) * 1987-02-02 1991-03-05 Eli Lilly And Company β-alkylmelatonins as ovulation inhibitors
EP0375726A4 (en) * 1987-08-17 1991-01-30 Whitby Research Incorporated Melatonin analogues
US5093352A (en) * 1988-11-14 1992-03-03 Whitby Research, Inc. Antidepressant agents
JPH0418034A (ja) * 1990-05-11 1992-01-22 Kanegafuchi Chem Ind Co Ltd 点眼組成物
US5242941A (en) * 1990-12-04 1993-09-07 State Of Oregon Methods of treating circadian rhythm disorders
IT1251544B (it) * 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
PT100973A (pt) * 1991-10-18 1994-06-30 Alza Corp Dispositivo e composicoes farmaceuticas para a administracao de melatonina por via transdermica
US5196435A (en) * 1991-11-21 1993-03-23 Eli Lilly And Company Melatonin derivatives and combinations with antiestrogen compounds for treating mammalian breast carcinoma
IT1255199B (it) * 1992-07-01 1995-10-20 Franco Fraschini Farmaco sintetizzato analogo della melatonina particolarmente efficacenelle patologie che interferiscono con i ritmi circadiani
IT1254995B (it) * 1992-06-24 1995-10-11 Farmaco contenente melatonina e/o agonisti, con somministrazione particolarmente efficace nelle patologie che interferiscono con i ritmi circandiani
US5449683A (en) * 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin

Also Published As

Publication number Publication date
NO944339D0 (no) 1994-11-14
EP0655243B1 (en) 2002-08-21
DE69431199D1 (de) 2002-09-26
DE69431199T2 (de) 2003-03-27
JPH07196493A (ja) 1995-08-01
CN1107701A (zh) 1995-09-06
DK0655243T3 (da) 2002-10-07
RU2146140C1 (ru) 2000-03-10
AU7777794A (en) 1995-05-25
SG50505A1 (en) 1998-07-20
US5654325A (en) 1997-08-05
ATE222491T1 (de) 2002-09-15
CZ288835B6 (cs) 2001-09-12
IL111580A0 (en) 1995-01-24
ZA948927B (en) 1996-05-10
PH31098A (en) 1998-02-05
NZ264892A (en) 1997-07-27
PT655243E (pt) 2002-11-29
HU9403300D0 (en) 1995-01-30
CN1092958C (zh) 2002-10-23
CZ276594A3 (en) 1995-07-12
EP0655243A3 (en) 1995-10-11
IL111580A (en) 1999-10-28
CA2135709A1 (en) 1995-05-19
HUT72069A (en) 1996-03-28
RU94040886A (ru) 1996-09-20
NO944339L (no) 1995-05-19
AU684313B2 (en) 1997-12-11
CA2135709C (en) 2007-01-02
NO309964B1 (no) 2001-04-30
ES2181702T3 (es) 2003-03-01
EP0655243A2 (en) 1995-05-31

Similar Documents

Publication Publication Date Title
KR880012218A (ko) 캘폰 유도체를 사용한 다발성 경화증의 치료방법
KR950013508A (ko) 수면 장애의 치료에 유용한 멜라토닌 유도체
ES2116801T3 (es) Empleo de derivados de adamantano para el tratamiento de tinnitus.
TW345575B (en) Pharmaceutical composition comprising an inhibitor for ras farnesylation and the preparation of the inhibitor compound
ATE8874T1 (de) Therapeutisch nuetzliche 1-alkyl-2-amino-tetralin- derivate.
ES2114645T3 (es) Utilizacion de un fosfato de alfa-tocoferol, o de uno de sus derivados para la preparacion de una composicion cosmetica, dermatologica o farmaceutica, de actividad anti-radicalar; composicion asi obtenida.
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
NO994091L (no) Medisinsk preparat inneholdende en lipofilisk inertgass
KR930012022A (ko) 뇌조직 보호용 모다피닐(Modafinil)
KR950010893A (ko) 자궁내막증 억제 방법
KR950010892A (ko) 자궁 섬유증 억제 방법
KR950013509A (ko) 비동기화 장애의 치료에 유용한 멜라토닌 유도체
DE69424009T2 (de) Verwendung von (S)-(-)-alpha-ethyl-2-oxo-1-pyrrolidinacetamid zur Herstellung eines Medikaments zur Behandlung von Angst
KR890011596A (ko) 불면증 치료용 의약품의 제조에 있어서 1,4-이치환-피페리디닐 화합물의 용도
KR950016727A (ko) 트롬보모듈린 발현을 증가시키는 방법
ES2103116T3 (es) Nuevos compuestos bi-aromaticos derivados de amida, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
ATE139690T1 (de) Ein ibuprofen enthaltendes akut-arzneimittel und seine verwendung
ES2103440T3 (es) Nuevas amidas y sulfonamidas naftalenicas, procedimiento de preparacion y composiciones farmaceuticas que las contienen.
ES2129112T3 (es) Compuestos aromaticos policiclicos, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
KR930017885A (ko) 항종양 조성물 및 종양의 치료방법
ES2090703T3 (es) Medicamento agudo que contiene flurbiprofeno y su empleo.
ES2046511T3 (es) Para-aminofenoles sustituidos en la posicion 2 y su utilizacion para la tincion de fibras queratinicas.
KR900015726A (ko) 이뇨제, 소염제 및 뇌혈제관제로서의 7-치환 아미노-8-치환 카르보닐-메틸아미노-1-옥사스피로[4,5]데칸
ATE12487T1 (de) Chlorierte betaketoester, ihre herstellung und anwendung.
KR900018128A (ko) 카르복스아미드 유도체

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
J201 Request for trial against refusal decision
AMND Amendment
B90T Transfer of trial file for re-examination
B601 Maintenance of original decision after re-examination before a trial
J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20040225

Effective date: 20050531

J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

J302 Written judgement (patent court)

Free format text: JUDGMENT (PATENT COURT) FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20050704

Effective date: 20060907